836 related articles for article (PubMed ID: 19420128)
1. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
2. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs.
Miraglia L; Pagliarusco S; Bordini E; Martinucci S; Pellegatti M
Drug Metab Dispos; 2010 Oct; 38(10):1876-91. PubMed ID: 20622044
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and characterization of drug-related material in rats and dogs after repeated oral administration of casopitant.
Pagliarusco S; Martinucci S; Bordini E; Miraglia L; Cufari D; Ferrari L; Pellegatti M
Drug Metab Dispos; 2011 Feb; 39(2):283-93. PubMed ID: 20978104
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret.
Minthorn E; Mencken T; King AG; Shu A; Rominger D; Gontarek RR; Han C; Bambal R; Davis CB
Drug Metab Dispos; 2008 Sep; 36(9):1846-52. PubMed ID: 18556439
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
[TBL] [Abstract][Full Text] [Related]
6. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
Colizza K; Awad M; Kamel A
Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
[TBL] [Abstract][Full Text] [Related]
7. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
9. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
10. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
Prakash C; Cui D; Potchoiba MJ; Butler T
Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
[TBL] [Abstract][Full Text] [Related]
11. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
12. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
[TBL] [Abstract][Full Text] [Related]
15. Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans.
Kamel A; Obach RS; Colizza K; Wang W; O'Connell TN; Coelho RV; Kelley RM; Schildknegt K
Drug Metab Dispos; 2010 Nov; 38(11):1984-99. PubMed ID: 20668248
[TBL] [Abstract][Full Text] [Related]
16. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
Prakash C; O'Donnell J; Khojasteh-Bakht SC
Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
[TBL] [Abstract][Full Text] [Related]
17. The disposition of prasugrel, a novel thienopyridine, in humans.
Farid NA; Smith RL; Gillespie TA; Rash TJ; Blair PE; Kurihara A; Goldberg MJ
Drug Metab Dispos; 2007 Jul; 35(7):1096-104. PubMed ID: 17403916
[TBL] [Abstract][Full Text] [Related]
18. Disposition of [14C]ruboxistaurin in humans.
Burkey JL; Campanale KM; Barbuch R; O'Bannon D; Rash J; Benson C; Small D
Drug Metab Dispos; 2006 Nov; 34(11):1909-17. PubMed ID: 16896067
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
Prakash C; Kamel A; Anderson W; Howard H
Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
[TBL] [Abstract][Full Text] [Related]
20. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]